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Abstract
Background: VEGF-regulated genes in the cervices of pregnant and non-pregnant rodents (rats
and mice) were delineated by DNA microarray and Real Time PCR, after locally altering levels of
or action of VEGF using VEGF agents, namely siRNA, VEGF receptor antagonist and mouse VEGF
recombinant protein.
Methods: Tissues were analyzed by genome-wide DNA microarray analysis, Real-time and gel-
based PCR, and SEM, to decipher VEGF function during cervical remodeling. Data were analyzed
by EASE score (microarray) and ANOVA (Real Time PCR) followed by Scheffe's F-test for multiple
comparisons.
Results: Of the 30,000 genes analyzed, about 4,200 genes were altered in expression by VEGF,
i.e., expression of about 2,400 and 1,700 genes were down- and up-regulated, respectively. Based
on EASE score, i.e., grouping of genes according to their biological process, cell component and
molecular functions, a number of vascular- and non-vascular-related processes were found to be
regulated by VEGF in the cervix, including immune response (including inflammatory), cell
proliferation, protein kinase activity, and cell adhesion molecule activity. Of interest, mRNA levels
of a select group of genes, known to or with potential to influence cervical remodeling were
altered. For example, real time PCR analysis showed that levels of VCAM-1, a key molecule in
leukocyte recruitment, endothelial adhesion, and subsequent trans-endothelial migration, were
elevated about 10 folds by VEGF. Further, VEGF agents also altered mRNA levels of decorin, which
is involved in cervical collagen fibrillogenesis, and expression of eNO, PLC and PKC mRNA, critical
downstream mediators of VEGF. Of note, we show that VEGF may regulate cervical epithelial
proliferation, as revealed by SEM.
Conclusion: These data are important in that they shed new insights in VEGF's possible roles and
mechanisms in cervical events near-term, including cervical remodeling.
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Cervical remodeling is considered a chronic inflamma-
tory-like process regulated by numerous factors, and its
dysfunction can potentially lead to birth-related compli-
cations [1-4]. Because the vasculature plays a crucial role
in inflammatory reactions, we have previously hypothe-
sized that factors that regulate the cervical vasculature are
likely to play a critical role in cervical remodeling, notably
VEGF and its associated molecules, such as nitric oxide.
For instance, local microvascular alterations during cervi-
cal remodeling may be essential for delivery of cells and
factors to the connective tissues for remodeling. In turn,
vascular-derived factors, such as leukocytes, play a critical
role in cervical remodeling by invading cervical tissue and
releasing catabolic enzymes and cytokines [5]. Thus,
recruitment or mobilization of leukocytes into the cervical
connective tissue may require structural changes to the
vasculature, and this process may be regulated, directly
and/or indirectly, by several factors.
VEGF is a member of a family of closely related growth
factors that include VEGF-A, -B, -C, -D, -E and placenta
growth factor (PIGF) [6]. VEGF-A has well-established
biological effects and exists as several splice variants [6].
Biological effects of VEGF are largely mediated by two
receptors: KDR (kinase domain region) and Flt-1 (fms-
like tyrosine kinase-1) [7,8]. The role of VEGF in female
reproductive biology is best known in the ovarian and
uterine events. VEGF is essential for a variety of ovarian
and uterine endometrial functions by mediating cyclical
growth of blood vessels. For instance, treatment with a
VEGF inhibitor (mFlt- [1-3]-IgG) virtually blocks corpus
luteum angiogenesis and maturation of endometrium [9].
VEGF signaling pathways for microvascular regulation
have been extensively studied to date, mostly in human
umbilical vein endothelial cells [HUVECs]. In spite of
this, very little is known about VEGF function in the cervix
in general and cervical remodeling in particular. We
recently reported that only VEGF variants 120 and 164
exist in the rat cervix [10]. In general, VEGF 164 is the
most abundant and best characterized of all VEGF variants
in the body. We also demonstrated that there exist two
VEGF receptors in the cervix of pregnant rats, namely KDR
and Flt-1, and that VEGF, its receptors, and some of its key
signaling molecules are altered in the cervix during preg-
nancy [10].
Although the mechanisms mediating specific vascular
effects of VEGF are beginning to be unraveled, they are not
fully elucidated and vary between vascular beds. A global
or genome-wide view of VEGF-related genes in the "ripen-
ing" cervix and knowledge of the specific VEGF/VEGF
receptor pathway mediating their cellular effects, is essen-
tial for obtaining a comprehensive evaluation of the proc-
esses (vascular and non-vascular) regulated by VEGF. In
this study, we alter VEGF action by either over-expressing,
down regulating or blocking VEGF action in the cervix of
non-pregnant and pregnant rodents (rat and mice) using
recombinant VEGF-protein, -siRNA generating pDNA or -
receptor antagonist (PTK787), respectively. Tissues were
analyzed using DNA microarray, gel-based PCR, Real-
Time PCR, SEM, and histology.
Methods
Animals and treatment with VEGF agents
a) Timed-pregnant Sprague Dawley rats [[17-20] gestation
day (GD); SASCO strain from Charles Rivers] were
divided into four groups (n = 5), based on treatment: a)
VEGF siRNA-generating pDNA (group 1; 40 μg/rat on
alternate days), b) VEGF inhibitor (PTK 787/ZK22584;
generously provided by Novartis Pharma AG, Basel, Swit-
zerland) (group 2; 1, 2.5, 5 mg/rat/on alternate days), c)
vehicle only (VEGF inhibitor control; group 3), and d)
vehicle with plasmid without VEGF siRNA insert (VEGF
siRNA control; group 4). The chemicals/nucleic acids were
pre-dissolved in 100 μl lipofectamine and mixed in 100 μl
saturated (25%) Pluronic F-127 (Sigma, St Louis) on ice.
The solution was then administered to the cervix via the
vagina using a 1-mL syringe on alternate days from GD17
to GD19. The animals were euthanized by a lethal injec-
tion of sodium pentobarbital (150 mg/kg bw), i.p., 12–24
hours later, on GD 20. Cervices were harvested, processed
and evaluated for changes in levels of VEGF mRNA and
whole genome gene expression using DNA microarray
data, as described below.
b) Pregnant mice and ovariectomized non-pregnant rats and
mice treated with either mouse recombinant VEGF protein
(10 ng/mouse recombinant VEGF; Calbiochem, La Jolla,
CA, once daily from GD13–17, intra-vaginally), VEGF
receptor antagonist (as described earlier, but treated
daily), or vehicle only, were utilized to confirm the DNA
microarray data above using real-time PCR, and for mor-
phological studies (SEM), described below. The animals
were euthanized by a lethal injection, as described earlier.
Cervices were harvested, processed and evaluated for
changes in levels of select genes (fold change > 2), and
SEM.
Generation and validation of VEGF siRNA-generating 
pDNA
Generation
We designed three pairs of VEGF siRNA oligos, annealed
and ligated them with a BamHI/HindIII restricted pSi-
lencer-3.0-H1 vector, separately. The recombined vectors
were transferred into E. coli DH5α, grown on ampicillin
(100μ/ml) LB dishes at 37°C over night. The clone for
each pDNA was obtained and confirmed by sequencing.
Validation
The VEGF gene silencing efficiency by the siRNA-generat-
ing pDNA was tested in vitro. Ten μg (in 250 μl water) ofPage 2 of 10
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fectamine 2000 (Eugene, Oregon) and used for rat heart
fibroblast primary cell transfection. The pDNA with the
best silencing efficiency was selected and used in the rat
cervix with either pluronic gel or Lipofectamine 2000, to
test its efficiency to down-regulate local cervical VEGF in
vivo.
Gene expression analysis
Overview
Changes in mRNAs levels of various genes in the cervices
of rats treated with VEGF agents were quantified using gel-
based PCR, DNA microarray, and real time PCR. Gel-
based PCR was also utilized to determine VEGF gene
silencing efficiency by the pairs of VEGF siRNA oligos in
the rat heart fibroblasts in vitro. DNA microarray data were
verified by real-time PCR.
Tissue processing and messenger RNA isolation
The animals were euthanized and transcardially perfused
with normal saline. The cervices were removed and stored
at -80°C until processing. Total RNA was isolated from
cervices of individual animals using RNeasy Mini Kit
(Qiagen, Valencia, CA). The amount and purity of total
RNA for each sample was estimated by spectrophotomet-
ric analysis at A260 and A280. The quality of RNA was
determined by agarose gel electrophoresis following SYBR
green™ (Invitrogen) staining. Aliquots of total RNA were
diluted in diethylpyrocarbonated (DEPC)-treated water
and stored at -80°C. The RNA quality and quantity for
DNA microarray analysis was determined, as described
under the DNA microarray section.
a) Gel-based PCR analysis: RNA preparation, RT-PCR and Gel-
based PCR
Gel-based PCR was employed to determine VEGF gene
silencing efficiency by the pairs of VEGF siRNA oligos in
the rat heart fibroblasts in vitro and the cervices of rats
treated with VEGF siRNA and control, as described earlier.
Total RNA from these two tissue-types was reverse tran-
scribed and amplified in an Eppendorf Master Cycler,
using reagents from Gene AMP Gold RNA PCR Kit (Perkin
Elmer BioSystems, Foster City, CA). The RNA was used in
RT-PCR to evaluate the total VEGF-A gene using as primers
5'-GTACCTCCACCATGCCAAGT-3' (sense) and 5'-
GCATTAGGGGCACACAGGAC-3' to generate a PCR
product of 194 bp [11]. Levels of VEGF genes were nor-
malized to the geometric mean of the internal control
gene, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
b) DNA microarray: Determination of RNA integrity and 
microarray statistical analysis
Integrity of total RNA was evaluated using capillary elec-
trophoresis (Bioanalyzer 2100, Agilent) and quantified
using a Nanodrop 1000 (Nanodrop, Wilmington, DE).
Following confirmation of RNA quality, Ovation™ Biotin
RNA Amplification and Labeling System (NuGen Tech-
nologies, Inc., San Carlos, CA) was used to prepare ampli-
fied, biotin-labeled cDNA from total RNA following
manufacturer's instructions. Briefly, first strand cDNA was
synthesized from 25 ng of total RNA using a unique first
strand DNA/RNA chimeric primer and reverse tran-
scriptase. Following double strand cDNA generation,
amplification of cDNA was achieved by utilizing an iso-
thermal DNA amplification process that involves repeated
SPIA™ DNA/RNA primer binding, DNA duplication,
strand displacement and RNA cleavage. The amplified
SPIA™ cDNA was purified and subjected to a two-step
fragmentation and labeling process. The fragmented/
biotinylated cDNA content was measured in a ND-1000
spectrophotometer and the quality was analyzed on an
RNA 6000 Nano LabChip (Agilent) using Agilent Bioana-
lyzer 2100. For each array, 2.2 μg of cDNA was hybridized
onto Rat Genome 230 2.0 GeneChips® (Affymetrix Inc.,
USA), containing more than 31,000 probe sets, analyzing
over 30,000 transcripts and variants from over 28,000
well-substantiated rat genes. Sequences used in the design
of the GeneChip Rat Genome 230 2.0 Array were selected
from GenBank®, dbEST, and RefSeq. The sequence clusters
were created from the UniGene database (Build 99, June
2002) and then refined by analysis and comparison with
the publicly available draft assembly of the rat genome
from the Baylor College of Medicine Human Genome
Sequencing Center (June 2002). Hybridization was
allowed to continue for 16 hours at 45°C, followed by
washing and staining of microarrays in a Fluidics Station
450 (Affymetrix Inc., USA). GeneChips were scanned in a
GeneChip Scanner 3000 (Affymetrix Inc., USA) and CEL
files were generated from DAT files using GeneChip®
Operating Software (GCOS) software (Affymetrix Inc.,
USA). The probe set signals were generated using the RMA
algorithm in ArrayAssist 3.4 (Stratagene) and were used to
determine differential gene expression by pair-wise com-
parisons. The genes that were altered by two-fold either
way were sorted and used for further interpretation of the
microarray data, and were also analyzed using the Expres-
sion Analysis Systematic Explorer (EASE), a software applica-
tion that facilitates biological interpretation of gene lists
derived from microarray, proteomic, and SAGE experi-
ments http://david.abcc.ncifcrf.gov/content.jsp?file=/
ease/ease1.htm&type=1. EASE helps identify biological
themes that are over-represented in array results. Finally,
data were analyzed using the cluster and scatter plots
(data not shown).
c) Real-time PCR. Real-time PCR procedure and statistical analysis
Real-time PCR was used to verify DNA microarray data.
Total RNA was DNase I treated, reverse transcribed, and
amplified as described above. The cDNA was then used toPage 3 of 10
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change of equal or greater than 2, including VEGF-A,
eNOS, decorin, PLCγ, PKC, VCAM-1, and oxytocin using
specific TaqMan Gene Expression Assays (Applied Biosys-
tems), which are pre-designed and pre-optimized gene-
specific probe sets. DNA amplification was performed
using the Applied Biosystems (ABI 7300 HT) Real-Time
PCR machine with the GeneAmp 7300 HT Sequence
detection system software (Perkin-Elmer Corp.). The PCR
reactions were set up in wells of a 96-well plate in a vol-
ume of 50 μl per well. The reaction components were: 2 μl
of synthesized cDNA, 25 μl of 2 × TaqMan Universal PCR
Mastermix, 2.5 μl of 20 × Assays-on-demand™ Gene Mix
(e.g., VEGF), and 20.5 μl of RNase-free water. The pro-
gram was set as follows: an initial step at 95°C for 10 min,
and then 40 cycles of 95°C for 15 s, and 60°C for 60 s.
The relative amount was calculated from the threshold
cycles with the instrument's software (SDS 2.0), according
to the manufacturer's instructions. Relative expression lev-
els of the target genes were normalized to the geometric
mean of the internal control gene, GAPDH. Data were
analyzed using Student's t test and ANOVA, followed by
Scheffe's F-test for multiple comparisons. P-values of <
0.05 were considered to be statistically significant.
Morphological studies
SEM studies were undertaken to visualize the effects of
VEGF agents on cervical morphology. Tissues were fixed
in 2.5% glutaraldehyde in 0.1 M PBS immediately after
sampling, and then washed in the buffer (0.1 M PBS).
After the washes, tissues were dehydrated in a graded eth-
anol series, and dried with a Polaron critical point drying
apparatus (Polaron Instruments Inc., Doylestown, PA).
All dried samples were mounted on aluminum stubs,
sputter coated with gold, and imaged with a Quanta 200
SEM (FEI Company, Hillsboro, OR) at 20 kV.
Results
VEGF gene silencing efficiency by siRNA-generating pDNA
a) Rat heart fibroblast primary cell
The three different pairs of VEGF siRNA-generating pDNA
transfected to rat heart fibroblast primary cell had differ-
ent silencing efficiency for VEGF. The pair with the best
efficiency was used in subsequent experiments (Figure 1).
b) Cervices of pregnant rats
VEGF siRNA-generating pDNA delivered to the cervix on
alternate days from GD17 to GD19 down-regulated about
half of VEGF mRNA by GD20, as revealed by gel-based
PCR data (Figure 2). Grossly, the cervices of rats treated
with VEGF siRNA appeared paler, compared to control
(data not shown). We interpreted this to mean reduced
vascular formation due to reduced VEGF levels. This inter-
pretation was also supported by the DNA microarray data
(See Table 1 and additional file 1 for the original data
used to perform this analysis).
Genome-wide delineation of VEGF-related genes by DNA 
microarray
DNA microarray analysis
As described earlier, gene expression profile of 30,000 rat
genes in the cervix of pregnant rats were analyzed follow-
ing intra vaginal treatment of rats during late gestation
with VEGF agents (siRNA and inhibitor).
VEGF siRNA-generating pDNA down regulates VEGF mRNA levels in rat heart fibroblastsFigure 1
VEGF siRNA-generating pDNA down regulates VEGF mRNA levels in rat heart fibroblasts. The VEGF gene 
silencing efficiency by the three siRNA-generating pDNAs were tested in vitro using rat heart fibroblast primary cell transfec-
tion. VEGF siRNA-generating pDNA was found to down-regulate VEGF in cultured rat heart fibroblasts compared to control. 
The pDNA with the best silencing efficiency was selected and used in the rat cervix to test its efficiency to down-regulate local 
cervical VEGF in vivo (see Figure 2). n = 5, (p < 0.05).Page 4 of 10
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Out of a total of 30,000 genes, about 4,200 genes had
altered gene expression at GD20, after intra vaginal
administration of the VEGF inhibitor. Of these, gene
expression of about 1,700 genes were up regulated (p <
0.05), while the rest, slightly over 2400, were down-regu-
lated (p < 0.05). These genes are annotated in the database
of NCBI's Reference Sequence project and are also found
on the annotation list of Code link. Although there was a
match between genes altered by VEGF siRNA and blocker,
the impact of VEGF siRNA, with an efficiency of about
50%, on gene expression was significantly less pro-
nounced compared to receptor antagonist. Only expres-
sion of about 300 genes were altered by VEGF siRNA, of
which about 50 were up regulated and about 220 were
down-regulated. Thus, henceforth, we will only focus on
data from VEGF receptor antagonist-treated animals.
Biological classification
We analyzed the data based on the EASE score, a robust
analytical tool that clusters altered gene expressions based
on cell component and molecular biological functions. It
was interesting to note that, based on this score, the "hall-
mark" biological processes of VEGF, and most processes
that may be relevant to cervical remodeling, were con-
nected and or regulated by VEGF in the cervix. This
included cell proliferation and motility, circulation,
immune and inflammatory responses, protein kinase
activity, calcium channel activity, tissue remodeling, heat
shock protein activity, and cell adhesion molecule activity
(See Table 1). Other processes, not "mainstream" to
VEGF-related processes, but known to play a role in cervi-
cal remodeling includes, steroid synthesis and metabo-
lism (See Table 1) and collagen metabolism.
Select groups of genes altered by VEGF agents include,
growth factors (e.g., EGF, FGF, IGF binding protein 1,
PGF, PDGF receptor, and TGFβ-1), inflammation-associ-
ated factors (e.g., chemokines, LPS binding proteins,
interferons, interleukins, and TNF), cervical matrix factors
(e.g., proteoglycans, hyaluronan acid, heparan sulfate,
and pro-collagen and collagen molecules), signaling mol-
ecules (e.g., PLCγ, PKC, AC 5, MAPKK 6, guanine nucle-
otide binding protein 13γ), neuronal factors (e.g., GABA A
receptor, galanin receptor 2, and α2a-adrenergic recep-
tor), vascular factors (e.g., VEGF C, endothelin receptor
type A, angiotensin II receptor, type 1, and angiopoietin
4), and factors involved in WBC migration (e.g., integrins
and a variety of cell adhesion molecules) (See additional
file 1 for the original data used to perform this analysis).
Real-time PCR analysis
Real-time PCR was used to verify DNA microarray data for
6 genes, namely VCAM-1, decorin, PLCγ, PKC, oxytocin,
and eNOS [See Figure 3 and additional file 1 for the orig-
inal data used to perform this analysis]. Data generated
from Real-time PCR analysis were found to be consistent
with the results from the DNA microarray.
SEM
SEM data demonstrated a pronounced increase in the
involutions of cervical epithelial sheet in VEGF protein-
treated mice compared to control (non-pregnant ovariec-
tomized) (Figure 4).
Discussion
Dysfunctional cervices are among the most important eti-
ologies of obstetrical complications, such as preterm and
protracted labor. Numerous studies have investigated the
roles of hormones, cytokines, prostaglandins, relaxin, and
leukocytes in cervical remodeling. However, the lack of a
comprehensive understanding of the exact factors trigger-
ing cervical remodeling and effective treatments empha-
Table 1: VEGF inhibitor (PTK787) alters various biological 
themes in cervix of pregnant rat.
Gene Category Ease score
Steroid Biosynthesis +6.11
Steroid Metabolism +4.97
Protein Kinase Activity ~+4
Cell Proliferation -8.11
Cell Motility -7.66
Circulation -3.16
Tissue Remodeling -3.16
Calcium Channel -2.5
Immune Response -4.70
Heat Shock Protein Activity -8.67
Cell Adhesion Molecule Activity -1.96
The biological processes, cellular components or molecular functions 
altered when VEGF action is blocked (VEGF inhibitor) during cervical 
remodeling (GD20), as revealed by DNA microarray analysis. n = 5.
VEGF siRNA-generating pDNA down regulates VEGF mRNA levels in rat cervixFigure 2
VEGF siRNA-generating pDNA down regulates 
VEGF mRNA levels in rat cervix. The VEGF gene silenc-
ing efficiency of the selected siRNA-generating pDNA was 
tested in vivo in the cervix of pregnant rat from GD17–20. 
VEGF siRNA-generating pDNA was found to down-regulate 
VEGF compared to control. n = 5, (p < 0.05).Page 5 of 10
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therapeutic interventions, such as vascular factors. To
date, virtually none have studied the role of cervical
microvasculature in cervical remodeling and how it may
impact parturition. The present study was designed to
identify signature genes that are commonly altered in cer-
vices of non-pregnant and pregnant rodents (mice and
rats) and the impact of altered VEGF action (blockade and
over-expression) on gene expression and morphology of
the cervix. The findings in these studies are novel and
important in that they address basic informational gaps
and demonstrate, for the first time, the potential role of
VEGF in cervical remodeling and factors involved in VEGF
action. However, the limitations of the present data are
that they only show alterations in mRNA levels and not
protein.
We previously demonstrated an association between
VEGF and its key signaling components, and based on
these data postulated that since vascular-derived factors
play important roles in cervical remodeling in general,
local microvascular alterations are essential for delivery of
these factors to cervical connective tissues for remodeling
to occur. Such vascular alterations include increased vas-
cular leakage; vasodilation, and vascular density and
expansion (angiogenesis); accompanied by alterations in
the synthesis of angiogenic factors [10,12]. Collectively,
these vascular changes increase the overall traffic of intra-
vascular factors, such as serum factors, fluids, nutrients,
and effector cells, and likely, in turn, enhance epithelial
cellular growth and proliferation and, thus, impact cervi-
cal remodeling. These structural and molecular alterations
in the vasculature are re-set to baseline levels immediately
after birth [10]. This postulation is consistent with data
from a later study that showed that VEGF alters the biome-
chanical properties of the cervix by diminishing tensile
strength [13].
To fully understand the functional role of VEGF, its path-
ways regulating cervical remodeling and microvascular
events, it is critical to map and identify "signature" genes
down-stream of or regulated by VEGF. This knowledge
would "fast-track" our efforts and will enable us to focus
on a small select number of VEGF- regulated genes. More-
over, it will expand our understanding of the relationship
between "signature" genes and the well-known regulators
of cervical remodeling, such as prostaglandins, IL-1, and
platelet growth factor that interestingly, are also known to
regulate VEGF in other tissues of the body [14-16]. It is
interesting to note that, based on the grouping of genes
according to their biological process, cell component, and
molecular functions using the EASE score, the "hallmark"
biological processes of VEGF, and most processes which
are relevant to cervical remodeling, are present and regu-
Mouse recombinant VEGF protein 164 up regulates gene expression of some genes in mouse cervixFig re 3
Mouse recombinant VEGF protein 164 up regulates gene expression of some genes in mouse cervix. Levels of 
eNOS, PKC, PLCγ, Decorin, Oxytocin and VCAM-1 mRNAs in the cervix of non-pregnant ovariectomized mice were up reg-
ulated by recombinant VEGF protein164 (10 ng/mice × 3 times/day for 3 days), as revealed by Real time PCR. n = 3, (p < 0.05).
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tein kinase activity, cell proliferation and motility,
circulation, ion channel activity, heat shock protein activ-
ity, immune response, and cell adhesion molecule activ-
ity. Other processes, not "mainstream" VEGF-related
processes, include regulation of tissue remodeling, steroid
synthesis, and metabolism.
Signaling mechanisms that underlie VEGF-induced vascu-
lar permeability appear to be context-and tissue-depend-
ent and are, in general, unclear [17]. For instance, VEGF-
induced formation of fenestrae is mediated by NO and
prostacyclin (PGI2), in some tissues [18,19], and inhibi-
tors of synthetic enzymes for these molecules (e.g., the
eNOS inhibitor L-NAME [a non-selective NOS inhibitor
that also inhibits inducible- and neuronal-NOS iso-
forms]) block VEGF-induced permeability changes in vivo
[20]. In contrast, VEGF-induced rat uterine venous hyper-
permeability involves calcium and phospholipase C-γ1
(PLCγ1), but not NO [21]. In the uterus, the best studied
signaling transduction believed to mediate VEGF-induced
vascular leakage, is mediated by PLC-γ1/DAG/IP3 path-
way, which leads to increased calcium influx and induc-
tion of the PKC pathway [21]. This signaling pathway
appears to be the most common pathway [21-25]. Inter-
estingly, here we show that VEGF agents (recombinant
protein and blocker) in the cervix alter mRNAs of eNOS,
PKC, and PLC-γ¹, using DNA microarray, and verified by
real time PCR. Thus, based on these data, VEGF likely reg-
ulates vascular leakage during cervical remodeling. Also,
of interest, the present DNA microarray data show that
several groups of cell adhesion molecules (ICAM,
integrin, VCAM-1, melanoma CAM, Cerebral endothelial
CAM) that play an essential role in WBC migration from
blood vessels to tissues are robustly regulated by VEGF
agents. Real time PCR data verified microarray data using
VCAM-1. However, at this point the exact pathways that
regulate cervical vascular permeability are not yet clear.
Other factors of interest that were altered by VEGF agents
include inflammatory, matrix, neuronal, vascular, and
growth factors. We have previously shown that sensory
neuronal factors influence cervical events, and that bilat-
eral neurectomy of the pelvic nerves diminished VEGF
protein levels in the cervix of pregnant rats [12]. Here, we
show that VEGF blocker also alters levels of neuronal fac-
tors in the cervix, suggesting a bidirectional or feedback
regulatory mechanism. It is also interesting to observe that
VEGF agents alter mRNA levels of notable inflammatory
factors, such as TNFα, LPS binding protein, and IL-1,
which is consistent with the proposition that cervical
remodeling is essentially a physiological inflammatory
response [4]. These data are also consistent with our
recent data showing that local induction of inflammation
Mouse recombinant VEGF protein 164 induces epithelial growth in mouse cervixFig re 4
Mouse recombinant VEGF protein 164 induces epithelial growth in mouse cervix. The effects of VEGF protein 
(mice recombinant VEGF164 protein, 10 ng/mouse × 3 times/day for 3 days, intravaginally) on cervical epithelial proliferation 
growth of non-pregnant ovexed mice, as revealed by SEM (A. Control, B, VEGF protein). Note pronounced involutions in 
treated (thin arrows) compared to shallow folds in control (thick arrows). Mag × 3,700. n = 3.Page 7 of 10
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mRNA [26]. Equally interesting is that fact that VEGF also
alters mRNA levels of key matrix factors known to be
involved in cervical remodeling, including decorin, colla-
gen, biglycan, hyaluronic acid, and heparin sulfate. Col-
lectively, these data, taken together with the
biomechanical data by Dussably et al., [13], strongly sug-
gests a role for VEGF in cervical remodeling.
Cervical remodeling is associated with increased epithe-
lial proliferation and edema [27,28]. In mice, cervical
edema is noticeable as early as GD12 and plateaus
between GD15–19, and, immediately thereafter, reaching
baseline levels by postpartum day 1 [29]. The exact func-
tion of edema and the mechanisms regulating its forma-
tion are not fully known. However, a number of factors
have been implicated, including, prostaglandins, sex ster-
oid hormones, relaxin, and aquaporins (subtypes 3, 4, 5
and 8) [30]. Furthermore, cervical epithelial cells, acting
via paracellular apical tight junction protein complex, are
known to maintain fluid balance (e.g., claudin 1 and 2)
[31]. One of the best studied factors implicated in edema
formation is hyaluronan, because of its high affinity for
water molecules, and because its levels increase dramati-
cally near term [32]. It has been proposed that hyaluronan
during cervical remodeling could modify tissue architec-
ture by increasing its volume and recruiting inflammatory
cells [32]. However, in mice, levels of hyaluronan only
significantly increase a few hours before labor, whereas
edema increases much earlier [30]. Here, we show by
microarray analysis that VEGF receptor antagonist down
regulates mRNA levels of hyaluronan. Thus, we suggest
VEGF as an additional candidate regulator of cervical
edema that may work together with or independent of
hyaluronan for the following reasons: a) vascular perme-
ability is the major contributor of tissue hydration and
VEGF, which was originally identified as an inducer of
vascular permeability factor from a guinea pig cell line
[33], is the most potent permeability factor known in the
body (50,000 times more potent than histamine)[34,35];
b) VEGF-induced vascular permeability is a major factor
underlying significant tissue hydration in multiple tissues
[36]; c) VEGF has been demonstrated to induce vascular
permeability via altering cellular junctions of endothelial
cells, e.g., creating fenestrae through which intravascular
solutes and fluids pass into the tissue [36,37]; d) VEGF
and its signaling molecules are present in the remodeling
cervix and have a temporal relationship with edema; e) In
the cervix, VEGF agents induce factors that are known to
mediate its vascular permeability effects, such as NO and
PKC; c) and finally, vascular leakage occurs during cervical
remodeling. Thus, here we postulate a working model that
suggests that during cervical remodeling, VEGF-induced
vascular leakage lead to protein extravasation, which in
turn, due to their strong hydrophilic properties (albumin
and fibrin), attract serum into the cervical tissue, and thus
leading to tissue hydration, cervical epithelial prolifera-
tion [38]. Further studies should validate this model and
the proposed effects of VEGF on cervical edema, as is seen
in most body tissue-types.
Cervical cellular activity and proliferation are particularly
pronounced in endocervical epithelial cells, i.e., epithelial
cells proliferate during pregnancy to occupy ~50% of the
entire cervix [30]. Cervical epithelial cells are now
believed to be involved in multiple and important func-
tions, during cervical remodeling, including: 1) maintain-
ing fluid balance via synthesis of hydrophilic hyaluronan,
glycosaminoglycan, and aquaporins, 2) proliferation and
differentiation, 3) regulation of paracellular transport of
solutes via tight junctions, 4) providing a protective bar-
rier against invading micro-organisms, and mediating
inflammatory and adaptive immune responses, 5) acting
as an "endocrine" gland by synthesizing prostaglandins,
chemokines and cytokines (e.g., interleukin-8), and ster-
oid hormones [39-42,30]. Thus, it is likely, as some inves-
tigators suggest, that cervical epithelial cells play the
central role in cervical remodeling. The best studied regu-
lators of cervical epithelial cell proliferation are relaxin
and sex steroid hormones [43]. However, the growth and
proliferation of these cells could also be regulated by
other factors, either in concert or independent of relaxin
and sex steroid hormones. For instance, the classical uter-
ine response to 17β-estradiol, namely increased epithelial
cell growth and proliferation, is mediated by VEGF via
increased vascular permeability and edema [44], and is
the case in other multiple tissue types [45-47]. Thus, it
seems that this phenomenal proliferation is wide spread
in the body. VEGF is known to induce epithelial growth
and proliferation during implantation, in fetal lung, pros-
tate, and also induces astroglial cell division in the brain
[45-47] via two mechanisms: 1) VEGF may stimulate
endothelial cells to secrete growth factors (e.g., FGF, IGF,
and PDGF) that, in turn, stimulate proliferation of neigh-
boring epithelial cells [48], or 2) VEGF may induce vascu-
lar permeability that leads to increase in infiltration of
local tissue and induction of epithelial growth by serum
factors, which are a rich source of growth factors [49]. This
later mechanism is supported by well established facts
that cells are functionally more active when cultured in
vitro in the presence of serum, and solid epithelial tumor
cells lacking adequate access to a blood supply will grow
only until passive diffusion can no longer provide ade-
quate nutrients [50,51,49]. Both mechanisms may be
operational in the cervix, and may, in part, account for the
phenomenal epithelial proliferation during cervical
remodeling, as revealed by our SEM data. Ongoing studies
in our lab are quantifying the effects of VEGF on epithelial
proliferation.Page 8 of 10
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Reproductive Biology and Endocrinology 2008, 6:64 http://www.rbej.com/content/6/1/64Conclusion
Here, we show that VEGF regulates levels of key factors
involved in a range of biological processes that lead to cer-
vical remodeling. We also show that VEGF induce cervical
epithelial growth. These data are novel and important in
that they shed new insights in VEGF's possible roles and
possible underlying mechanisms during cervical remode-
ling.
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